A Study of IBI362 in Chinese Patients With Type 2 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 252 participants.

Also called NCT04965506

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 252 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04965506
Other papers using this trial's data
  • Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial Diabetes care, 2024-01-01 DOI, PubMed 37943529, PMC10733643 In the PMC Open Access subset under a licence that is not Creative Commons.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04965506. Randomized; double masking; primary purpose treatment. Start 2021-09-06 (actual); primary completion 2022-04-28 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
Intervention (Drug)
IBI362
Intervention (Other)
placebo
Intervention (Other)
Dulaglutide
Lead sponsor
Innovent Biologics (Suzhou) Co. Ltd. (class: industry)

Record details

Record id
cardio:ct-nct04965506
Content hash
9c4cd4b64f55b3340651f4949ed39ac599a0af51fe579f4bd14b6340bf52268c